current
pandem
caus
coronaviru
close
relat
sar
mer
humbl
begin
late
wuhan
china
rapidli
spread
major
nation
midmarch
pandem
stir
worldwid
havoc
higher
infect
rate
associ
variabl
advers
outcom
across
countri
far
affect
countri
develop
west
south
european
north
american
countri
along
china
iran
asian
countri
alreadi
kill
thousand
peopl
th
april
analysi
commun
plan
exponenti
increas
death
everi
pass
day
pandem
sent
countri
health
servic
scrambl
decreas
fallout
dedic
worldwid
platform
creat
provid
uptod
inform
pandem
overal
recoveri
rate
make
countri
panic
consolid
resourc
decreas
death
today
th
april
death
ascrib
alreadi
cross
thousand
mark
variou
clinic
trial
repurpos
exist
drug
indic
similar
coronaviru
suggest
patholog
well
experiment
vaccin
initiatedplan
larg
number
studi
also
conduct
result
publish
journal
post
onlin
preprint
server
medrxiv
biorxiv
understand
basi
differenti
incid
fatal
rate
differ
countri
studi
indic
exist
posit
correl
bcg
vaccin
polici
inher
resist
popul
suggest
clinic
trial
evalu
prevent
potenti
data
avail
need
analyz
thoroughli
arriv
action
contextspecif
conclus
amelior
devast
effect
human
live
bacil
bcg
vaccin
primarili
given
protect
tuberculosi
tb
countri
higher
tb
incid
tb
remain
top
caus
death
singl
pathogen
mycobacterium
tuberculosi
mtb
vaccin
bcg
exposur
environment
nontubercul
mycobacteria
suppos
train
cellmedi
immun
respond
better
subsequ
exposur
intracellular
pathogen
mtb
respond
cell
product
variou
cytokin
includ
also
key
cytokin
innat
adapt
immun
viral
bacteri
infect
gener
longterm
crossreact
protect
effect
sever
pathogen
suggest
longterm
epigenet
program
train
immun
cell
particularli
macrophag
nkcell
mycobacteri
exposur
bcg
environment
bcg
vaccin
found
provid
protect
immun
variabl
durat
differ
popul
rang
year
year
howev
note
case
mtb
get
clear
even
absenc
bcg
vaccin
prior
train
immun
system
bcg
vaccin
prevent
primari
infect
mtb
activ
latent
tb
infect
ltbi
suppos
limit
effect
prevent
mtb
spread
popul
suppos
protect
immun
wane
away
time
subsequ
exposur
environment
mycobacteria
could
act
booster
keep
immun
intact
exposur
mycobacterium
spp
whether
mtb
bcg
vaccin
environment
isol
usual
test
tuberculin
sensit
test
tst
interferon
gamma
releas
assay
igra
current
analysi
conduct
ascertain
effect
preval
immun
respons
mycobacterium
spp
select
popul
suscept
intend
provid
evid
make
inform
decis
policymak
april
univers
bcg
vaccin
polici
actual
estim
bcg
vaccin
coverag
healthcar
access
qualiti
haqi
index
neglect
tropic
diseas
ntd
tuberculosi
incid
present
figur
consid
countri
contribut
major
case
incid
rate
case
per
million
appear
higher
bracket
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
economi
hqi
index
see
fig
appar
better
healthcar
hygien
puzzlingli
translat
higher
incid
recent
propos
earlier
implement
univers
bcg
polici
could
respons
lower
incid
bcg
vaccin
gener
given
children
high
tb
preval
countri
protect
develop
pulmonari
tb
vaccin
estim
protect
differ
popul
variabl
durat
rang
year
bcg
induc
delay
tcell
mediat
hypersensit
suppos
protect
train
immun
system
respond
disciplin
manner
without
get
overwhelm
cytokin
storm
expos
pathogen
compar
incid
among
differ
countri
bcg
vaccin
polici
implement
figur
total
bcg
coverag
figur
seem
affect
confirm
death
per
million
popul
specif
countri
eg
australia
usa
germani
countri
fall
less
bcg
coverag
region
seemingli
display
dispar
outcom
concern
coronaviru
death
eg
finland
sweden
south
africa
iran
greenland
iceland
etc
hypothes
mayb
overal
burdenincid
tb
neglect
tropic
diseas
ntd
may
display
better
correl
death
compar
incid
tb
ntd
burden
popul
seem
affect
countri
lower
diseas
burden
especi
tb
overal
observ
total
confirm
death
per
million
popul
among
differ
countri
seem
correl
neg
tuberculosi
incid
coverag
bcg
vaccin
bcg
vaccin
polici
implement
expect
diseas
burden
may
provid
nonspecif
protect
reason
nonspecif
protect
immun
work
due
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
promin
tourist
destin
econom
workhors
inher
exchang
larg
flux
visitor
case
fatal
rate
ratio
cfr
estim
probabl
someon
case
may
die
contract
diseas
cfr
estim
known
vari
locat
phase
outbreak
screen
criteria
adopt
extent
screen
report
issu
number
case
identifiedreport
support
health
care
etc
pandem
still
underway
true
cfr
reliabl
ascertain
rather
guess
allow
us
understand
evolv
epidemiolog
cfr
valu
covid
recent
estim
germani
itali
evalu
whether
bcg
vaccin
may
provid
certain
degre
protect
correl
peopl
countri
report
high
bcg
coverag
high
tstigra
posit
calcul
cfr
set
countri
report
case
use
definit
cfr
total
death
diseas
total
number
case
report
x
plot
vs
ltbi
tstigra
posit
figur
cfr
valu
rang
among
countri
countri
lower
ltbi
total
seem
higher
cfr
next
countri
higher
ltbi
howev
note
lower
cfr
display
countri
higher
ltbi
averag
also
suppos
rel
earlier
phase
pandem
except
china
account
total
death
includ
china
moment
though
neg
correl
obtain
would
tenuou
get
realist
action
estim
current
emerg
situat
project
purpos
estim
interim
infect
fatal
rate
ratio
iifr
use
definit
iifr
total
death
diseas
total
number
case
outcom
x
estim
requir
assess
graviti
situat
lowest
possibl
ifr
iifrl
calcul
best
possibl
outcom
scenario
includ
dead
recov
total
number
case
outcom
highest
possibl
ifr
iifrh
calcul
worst
possibl
outcom
scenario
consid
critic
sick
dead
categori
possibl
rest
similar
iifrl
calcul
done
get
realist
estim
problem
two
reason
current
complet
pictur
cours
estim
chines
outbreak
project
period
week
appear
first
symptom
death
predictedproject
death
rate
best
possibl
scenario
iifrl
critic
sick
recov
rang
iceland
uk
worstcas
scenario
estim
iifrh
critic
sick
may
die
vari
korea
uk
see
supplementari
file
sheet
tabl
figur
interest
note
differ
observ
cfr
iifrl
iifrh
estim
quit
surpris
across
countri
cfr
iifrl
increas
lowest
less
china
wit
increas
uk
netherland
everi
countri
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
context
differ
variabl
need
identifi
better
manag
howev
iifrl
iifrh
estim
plot
vs
increas
ltbi
posit
differ
countri
popul
appar
correl
infer
could
made
figur
ltbi
posit
countri
sever
ifr
larg
variat
observ
estim
infect
fatal
rate
ie
iifrl
iifrh
differ
countri
almost
credibl
explain
avail
data
specul
larg
variat
could
result
countri
differ
stage
pandem
well
inher
differ
affect
popul
demographi
comorbid
genet
makeup
also
indic
select
popul
south
korea
spain
china
itali
detail
compar
analysi
person
health
record
patient
final
outcom
ie
dead
recov
sick
along
genet
avail
need
perform
wherev
possibl
affect
countri
better
understand
underli
confound
variabl
affect
outcom
also
design
better
strategi
manag
next
get
better
pictur
underli
mechan
concern
role
ltbi
target
popul
divid
select
countri
top
countri
account
surprisingli
countri
seemingli
worsthit
regard
total
number
death
seemingli
lower
ifr
iifr
iifrh
eg
itali
cfr
spain
cfr
compar
mani
other
current
seem
less
sever
affect
eg
uk
cfr
netherland
cfr
iifrh
current
combin
estim
countri
stand
next
compar
countri
fatal
rate
estim
bottom
countri
countri
account
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
death
present
comparison
bar
diagram
figur
urgent
need
identifi
risk
factor
may
promot
advers
outcom
risk
variabl
age
cardiovascular
diseas
chronic
respiratori
diseas
diabet
alreadi
identifi
associ
advers
outcom
select
popul
eg
itali
south
korea
spain
china
etc
potenti
caus
associ
need
verifi
popul
well
underli
mechan
respons
advers
outcom
need
elucid
caus
precis
identifi
take
correct
measur
decreas
overal
mortal
would
also
interest
investig
underli
issu
report
data
collect
identifi
protect
contributori
factor
may
respons
dispar
outcom
differ
virul
viru
strain
current
affect
differ
popul
train
statu
immun
system
deal
intracellular
pathogen
exposur
mycobacteriabcgtst
posit
mount
measur
immun
respons
without
buckl
cytokin
storm
predict
infect
could
risk
factor
select
populationsgroup
bcg
vaccin
may
primari
caus
lower
infect
mortal
rate
per
million
popul
observ
select
countri
adopt
univers
bcg
polici
earli
cover
entir
popul
vaccin
though
idea
exposur
environment
mycobacterium
spp
bcg
vaccin
could
train
bodi
respond
intracellular
pathogen
better
complet
discount
margin
benefit
could
supposedli
gain
would
limit
specif
popul
subgroup
suscept
develop
tb
countri
huge
dispar
case
fatal
rate
among
low
ltbi
bcg
coverag
countri
high
itali
spain
usa
etc
vs
low
germani
switzerland
austria
iceland
high
ltbi
bcg
coverag
countri
high
brazil
philippin
indonesia
etc
vs
low
japan
china
mexico
africa
korea
thailand
etc
larg
variat
cfr
importantli
estim
interim
ifr
among
countri
could
result
inher
popul
constitut
eg
genet
age
underli
comorbid
eg
cardiovascular
diseas
diabet
age
hiv
statu
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
inflammatori
diseas
like
rheumatoid
arthriti
due
differ
inher
virulencepathogen
viru
strain
current
circul
differ
region
underli
caus
differ
fatal
rate
among
differ
countri
popul
need
understood
govern
agenc
may
collect
make
avail
patient
specif
data
pertain
allow
closer
scrutini
make
better
inform
decis
correl
analysi
immun
marker
variat
hla
type
genet
background
inform
may
alreadi
avail
readili
obtain
develop
countri
also
current
affect
countri
studi
explor
correl
genet
makeup
patient
ie
critic
recov
deceas
along
asymptomat
display
nonseri
symptom
may
activ
promot
taken
prioriti
basi
time
variou
intern
bodi
govern
agenc
philanthropist
come
forward
allow
kind
retrospectiveprospect
work
undertaken
better
understand
adversari
current
situat
warrant
research
organ
group
requir
resourc
brought
togeth
work
unison
toward
common
goal
contain
spread
devast
war
foot
window
opportun
may
close
rate
faster
perceiv
fund
support
banara
hindu
univers
laboratori
ss
acknowledg
author
grate
acknowledg
fruit
construct
discuss
subject
professor
rakesh
bhatnagar
jawaharl
nehru
univers
new
delhi
india
help
take
current
form
figur
b
e
f
http
ourworldindataorgcoronaviru
c
http
wwwwhointimagesdefaultsourcemapsglobaltbbcgvaccin
respect
entiti
use
noncommerci
purpos
fair
use
entiti
wherev
applic
permiss
copyhold
may
sought
commerci
reproduct
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
